Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes

Abstract

Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) tablets. Data Sources: Searches of MEDLINE (1946 to July 1, 2017) were conducted using the keywords QTERN, saxagliptin, and dapagliflozin. Additional data were obtained from the prescribing information, the product dossier, and Clinicaltrials.gov. Study Selection and Data Extraction: All English language articles related to pharmacology, pharmacokinetics, efficacy, or safety of the combination therapy in human subjects were reviewed. Data Synthesis: The pharmacokinetics of saxagliptin and dapagliflozin were not affected significantly when administered as an FDC product. Saxagliptin may suppress the increased secretion of glucagon associated with dapagliflozin. The combination dapagliflozin/saxagliptin has been studied as add-on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus (T2DM). The difference in hemoglobin A_1C (A1C) between saxagliptin + dapagliflozin + metformin (triple therapy) and saxagliptin + metformin was −0.59 (95% CI = −0.81 to −0.37, P < 0.0001), and the difference between triple therapy and dapagliflozin + metformin was −0.27 (95% CI = −0.48 to −0.05, P = 0.0166). The combination was well tolerated when added to metformin. Conclusion: QTERN (dapagliflozin/saxagliptin) tablets are a reasonable option for patients with T2DM not controlled on metformin, but cost, insurance coverage, and a lackluster reduction in A1C will likely limit its use until more data regarding its effects on complications of diabetes and cardiovascular outcomes become available.

Keywords

QTERN saxagliptin dapagliflozin dipeptidyl peptidase 4 inhibitor sodium-glucose cotransporter 2 inhibitor type 2 diabetes

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017: estimates of diabetes and its burden in the United States. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed August 10, 2017.

American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(suppl 1):S64-S75. doi:10.2337/dc17-S011

Bennett

Maruthur

Singh

et al . Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602-613. doi:10.7326/0003-4819-154-9-201105030-00336

Abdul-Ghani

Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?

Diabetes Care. 2015;38:373-375. doi:10.2337/dc14-2517

QTERN (dapagliflozin/saxagliptin) [product information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.

Scheen

AJ.

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol. 2016;12:1407-1417. doi:10.1080/17425255.2016.1215427

Bristol-Myers Squibb. U.S. Food and Drug Administration approves Onglyza (saxagliptin) for the treatment of type 2 diabetes mellitus in adults. https://news.bms.com/press-release/rd-news/us-food-and-drug-administration-approves-onglyza-saxagliptin-treatment-type-2-. Accessed August 30, 2017.

AstraZeneca. US FDA approves Farxiga (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes. https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-farxiga-treatment-type-2-diabetes-patients-13012014.html#!. Accessed May 25, 2017.

AstraZeneca. AstraZeneca receives Complete Response Letter from US FDA for saxagliptin/dapagliflozin fixed-dose-combination. https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-receives-complete-response-letter-from-us-16102015.html. Accessed May 25, 2017.

10.

AstraZeneca. FDA approves once-daily QTERN (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes. https://www.astrazeneca.com/media-centre/press-releases/2017/fda-approves-once-daily-qtern-dapagliflozin-and-saxagliptin-tablets-for-adults-with-type-2-diabetes-240217.html. Accessed May 25, 2017.

11.

Bays

From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009;25:671-681. doi:10.1185/03007990802710422

12.

Wright

Loo

Hirayama

BA.

Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733-794. doi:10.1152/physrev.00055.2009

13.

Abdul-Ghani

Norton

Defronzo

RA.

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-531. doi:10.1210/er.2010-0029

14.

Anderson

Marrs

JC.

Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother. 2012;46:590-598. doi:10.1345/aph.1Q538

15.

Salehi

Aulinger

Prigeon

D’Alessio

DA.

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes. 2010;59:1330-1337. doi:10.2337/db09-1253

16.

Deacon

Holst

JJ.

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type2 diabetes. Adv Ther. 2009;26:488-499. doi:10.1007/s12325-009-0030-9

17.

Tahrani

Piya

Barnett

AH.

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26:249-262. doi:10.1007/s12325-009-0014-9

18.

Merovci

Solis-Herrera

Daniele

et al . Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509-514. doi:10.1172/JCI70704

19.

Ferrannini

Muscelli

Frascerra

et al . Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499-508. doi:10.1172/JCI72227

20.

Rosenstock

Hansen

Zee

et al . Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapgliflozin to metformin. Diabetes Care. 2015;38:376-383. doi:10.2337/dc14-1142

21.

Hansen

Iqbal

Ekholm

et al . Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract. 2014;20:1187-1197. doi:10.4158/EP14489

22.

ClinicalTrials.gov. Bioequivalence study coadministered to healthy subjects in the fasted state. https://clinicaltrials.gov/ct2/show/NCT02223065. Accessed May 25, 2017.

23.

Borja-Hart

Whalen

KL.

Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes. Ann Pharmacother. 2010;44:1046-1053. doi:10.1345/aph.1P003

24.

Aylsworth

Dean

VanNorman

Okere

AN.

Dapagliflozin for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2014;48:1202-1208. doi:10.1177/1060028014540450

25.

Matthaei

Catrinouiu

Celinki

et al . Randomized, double-blind, trial of trip therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care. 2015;38:2018-2024. doi:10.2337/dc15-0811

26.

Mathieu

Ranetti

et al . Randomized, double-blind phase 3 trial of trip therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38:2009-2017. doi:10.2337/dc15-0779

27.

Rohwedder

Ekholm

Cook

et al . Dual treatment with saxagliptin and dapagliflozin provides a similar increase in urinary glucose excretion with few genitourinary infections compared with dapagliflozin. Diabetes. 2015;64(suppl 1):1208-P. doi:10.2337/db15-932-1471

28.

DeFronzo

Lewin

Patel

et al . Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384-393. doi:10.2337/dc14-2364

29.

Scirica

Bhatt

Braunwald

et al . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326. doi:10.1056/NEJMoa1307684

30.

ClinicalTrials.gov. Dapagliflozin AND cardiovascular. https://clinicaltrials.gov/ct2/results?term=dapagliflozin+AND+cardiovascular&Search=Search. Accessed May 25, 2017.

31.

ClinicalTrials.gov. Saxagliptin AND dapagliflozin. https://clinicaltrials.gov/ct2/results?term=saxagliptin+AND+dapagliflozin&Search=Search. Accessed May 25, 2017.

32.

Ptaszynska

Cohen

Messing

et al . Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a “case study.” Diabetes Ther. 2015;6:357-375. doi:10.1007/s13300-015-0128-9

33.

Andrianesis

Glykofridi

Doupis

The renal effects of SGLT2 inhibitors and a mini-review of the literature. Adv Endocrinol Metab. 2016;7:212-228. doi:10.1177/2042018816676239

34.

American Diabetes Association. Erratum. Cardiovascular disease and risk management: sec. 9. Standards of medical care in diabetes-2017. Diabetes Care. 2017;40(suppl 1):S75-S87. doi:10.2337/dc17-S012

35.

American Diabetes Association. Erratum. Microvascular complications and foot care: sec. 10. Standards of medical care in diabetes-2017. Diabetes Care. 2017;40(suppl 1):S88-S98. doi:10.2337/dc17-S013

36.

American Diabetes Association. Erratum. Pharmacologic approaches to glycemic treatment: sec. 8. Standards of medical care in diabetes-2017. Diabetes Care. 2017;40(suppl 1):S64-S75. doi:10.2337/dc17-S011

37.

Filion

Suissa

DPP-4 inhibitors and heart failure: some reassurance, some uncertainty. Diabetes Care. 2016;39:735-737. doi:10.2337/dci15-0036

38.

Food and Drug Administration. FDA Drug Safety Communication. FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. https://www.fda.gov/Drugs/DrugSafety/ucm486096.htm. Accessed July 11, 2017.

39.

Dandona

Chauduri

Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: an overview for the primary care physician. Int J Clin Pract. 2017;71(5). doi:10.1111/ijcp.12937

40.

Lilly. US FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes. https://investor.lilly.com/releasedetail.cfm?releaseid=894045. Accessed May 25, 2017.

41.

Zinman

Wanner

Lachin

et al ; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi:10.1056/NEJMoa1504720

42.

Marso

Daniels

Brown-Frandsen

et al ; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322. doi:10.1056/NEJMoa1603827

43.

Glyxambi (empagliflozin/linagliptin) [product information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2017.

44.

Boehringer Ingelheim. CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. https://clinicaltrials.gov/show/NCT01243424. Accessed June 21, 2016.

45.

Bell

DS.

Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15:291-300. doi:10.1111/dom.12015

46.

Jarab

Almrayat

Alqudah

Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes. Int J Clin Pharm. 2014;36:725-733. doi:10.1007/s11096-014-9938-5

47.

Hutchins

Zhang

Fleurence

Krishnarajah

Graham

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157-1168. doi:10.1185/03007995.2011.570745